Clinical Trial

CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 15, 2025 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy of CMV-specific T cell immunity test in prolonged usage of letermovir for avoiding late-onset csCMVi after all-HSCT.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-06-05; most recent amendment 2025-12-06.
Status change: Recruiting → Active, Not Recruiting 2025-12-06
Status change: Not Yet Recruiting → Recruiting 2025-01-07
Trial Details
NCT Number NCT06449586
Lead Sponsor Ruijin Hospital
Conditions Hematologic Malignancy
Enrollment 250 participants
Start Date 2024-07-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-15